Exicure, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
XCUR Nasdaq 2830 www.exicuretx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Exicure, Inc.

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance - Aug 3rd, 2026 7:24 am
Exicure Announces Board and Committee Changes - Jun 30th, 2026 6:40 am
Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement - Jun 10th, 2026 2:01 pm
Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q - Jun 1st, 2026 2:00 pm
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) - Apr 22nd, 2026 5:54 pm
Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions - Apr 2nd, 2026 2:01 pm
Exicure, Inc. Reports Full Year 2025 Financial Results - Mar 25th, 2026 2:18 pm
Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant - Feb 5th, 2026 5:00 am
Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings - Jan 21st, 2026 5:00 am
Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting - Dec 8th, 2025 2:30 pm